These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 18588590)

  • 1. Predictors of antidepressant response to fluvoxamine obtained using the three-factor structures of the Montgomery and Asberg Depression Rating Scale for major depressive disorders in Japanese patients.
    Higuchi H; Sato K; Yoshida K; Takahashi H; Kamata M; Otani K; Yamaguchi N
    Psychiatry Clin Neurosci; 2008 Jun; 62(3):301-6. PubMed ID: 18588590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. No predictors of antidepressant patient response to milnacipran were obtained using the three-factor structures of the Montgomery and Asberg Depression Rating Scale in Japanese patients with major depressive disorders.
    Higuchi H; Sato K; Yoshida K; Takahashi H; Kamata M; Otani K; Yamaguchi N
    Psychiatry Clin Neurosci; 2008 Apr; 62(2):197-202. PubMed ID: 18412843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of response to electroconvulsive therapy obtained using the three-factor structure of the Montgomery and Asberg Depression Rating Scale for treatment-resistant depressed patients.
    Okazaki M; Tominaga K; Higuchi H; Utagawa I; Nakamura E; Noguchi M; Itaya M; Hashimoto C; Yamaguchi N
    J ECT; 2010 Jun; 26(2):87-90. PubMed ID: 19710622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gender differences in the clinical effects of fluvoxamine and milnacipran in Japanese major depressive patients.
    Naito S; Sato K; Yoshida K; Higuchi H; Takahashi H; Kamata M; Ito K; Ohkubo T; Shimizu T
    Psychiatry Clin Neurosci; 2007 Aug; 61(4):421-7. PubMed ID: 17610668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparative study of the efficacy and safety profiles between fluvoxamine and nortriptyline in Japanese patients with major depression.
    Otsubo T; Akimoto Y; Yamada H; Koda R; Aoyama H; Tanaka K; Mimura M; Nakagome K; Kamijima K
    Pharmacopsychiatry; 2005 Jan; 38(1):30-5. PubMed ID: 15706464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concentration-response relationship for fluvoxamine using remission as an endpoint: a receiver operating characteristics curve analysis in major depression.
    Suzuki Y; Fukui N; Sawamura K; Sugai T; Watanabe J; Ono S; Inoue Y; Ozdemir V; Someya T
    J Clin Psychopharmacol; 2008 Jun; 28(3):325-8. PubMed ID: 18480690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A three-factor model of the MADRS in major depressive disorder.
    Suzuki A; Aoshima T; Fukasawa T; Yoshida K; Higuchi H; Shimizu T; Otani K
    Depress Anxiety; 2005; 21(2):95-7. PubMed ID: 15884092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does early improvement triggered by antidepressants predict response/remission? Analysis of data from a naturalistic study on a large sample of inpatients with major depression.
    Henkel V; Seemüller F; Obermeier M; Adli M; Bauer M; Mundt C; Brieger P; Laux G; Bender W; Heuser I; Zeiler J; Gaebel W; Mayr A; Möller HJ; Riedel M
    J Affect Disord; 2009 Jun; 115(3):439-49. PubMed ID: 19027961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low frequency (1-Hz), right prefrontal repetitive transcranial magnetic stimulation (rTMS) compared with venlafaxine ER in the treatment of resistant depression: a double-blind, single-centre, randomized study.
    Bares M; Kopecek M; Novak T; Stopkova P; Sos P; Kozeny J; Brunovsky M; Höschl C
    J Affect Disord; 2009 Nov; 118(1-3):94-100. PubMed ID: 19249105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic association analysis of functional polymorphisms in neuronal nitric oxide synthase 1 gene (NOS1) and mood disorders and fluvoxamine response in major depressive disorder in the Japanese population.
    Okumura T; Kishi T; Okochi T; Ikeda M; Kitajima T; Yamanouchi Y; Kinoshita Y; Kawashima K; Tsunoka T; Inada T; Ozaki N; Iwata N
    Neuropsychobiology; 2010; 61(2):57-63. PubMed ID: 20016223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic efficacy assessment of weak variable magnetic fields with low value of induction in patients with drug-resistant depression.
    Sobiś J; Jarzab M; Hese RT; Sieroń A; Zyss T; Gorczyca P; Gierlotka Z; Pudlo R; Matysiakiewicz J
    J Affect Disord; 2010 Jun; 123(1-3):321-6. PubMed ID: 19896204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of imipramine, fluvoxamine and depressive mood on autonomic cardiac functioning in major depressive disorder.
    Volkers AC; Tulen JH; van den Broek WW; Bruyn JA; Passchier J; Pepplinkhuizen L
    Pharmacopsychiatry; 2004 Jan; 37(1):18-25. PubMed ID: 14750044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Orphan nuclear receptor Rev-erb alpha gene (NR1D1) and fluvoxamine response in major depressive disorder in the Japanese population.
    Kishi T; Kitajima T; Ikeda M; Yamanouchi Y; Kinoshita Y; Kawashima K; Okochi T; Ozaki N; Iwata N
    Neuropsychobiology; 2009; 59(4):234-8. PubMed ID: 19571598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination from treatment initiation.
    Blier P; Gobbi G; Turcotte JE; de Montigny C; Boucher N; Hébert C; Debonnel G
    Eur Neuropsychopharmacol; 2009 Jul; 19(7):457-65. PubMed ID: 19345072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Escitalopram in the treatment of major depressive disorder in primary-care settings: an open-label trial.
    Chokka P; Legault M
    Depress Anxiety; 2008; 25(12):E173-81. PubMed ID: 19006260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and validation of the Affective Self Rating Scale for manic, depressive, and mixed affective states.
    Adler M; Liberg B; Andersson S; Isacsson G; Hetta J
    Nord J Psychiatry; 2008; 62(2):130-5. PubMed ID: 18569776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An open-label multicentric study of the tolerability and response to escitalopram treatment in Indian patients with major depressive disorder.
    Pinto C; Trivedi JK; Vankar GK; Sharma PS; Narasimha V
    J Indian Med Assoc; 2007 Jul; 105(7):364, 366, 368 passim. PubMed ID: 18178988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effective dose of escitalopram in moderate versus severe DSM-IV major depression.
    Bech P; Andersen HF; Wade A
    Pharmacopsychiatry; 2006 Jul; 39(4):128-34. PubMed ID: 16871468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation of the Depression and Somatic Symptoms Scale by comparison with the Short Form 36 scale among psychiatric outpatients with major depressive disorder.
    Hung CI; Wang SJ; Liu CY
    Depress Anxiety; 2009; 26(6):583-91. PubMed ID: 19242983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of response to fluvoxamine in nondemented elderly compared to younger patients affected by major depression.
    Zanardi R; Cusin C; Rossini D; De Ronchi D; Serretti A
    J Clin Psychopharmacol; 2003 Dec; 23(6):535-9. PubMed ID: 14624182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.